|
1
|
Wang SS, Vajdic CM, Linet MS, Slager SL,
Voutsinas J, Nieters A, de Sanjose S, Cozen W, Alarcón GS,
Martinez-Maza O, et al: Associations of non-Hodgkin lymphoma (NHL)
risk with autoimmune conditions according to putative NHL loci. Am
J Epidemiol. 181:406–421. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cereser L, Passarotti E, De Pellegrin A,
Patruno V, Poi ED, Marchesini F, Zuiani C and Girometti R: Chest
high-resolution computed tomography in patients with connective
tissue disease: Pulmonary conditions beyond ‘the usual suspects’.
Curr Probl Diagn Radiol. 51:759–767. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Khanmohammadi S, Shabani M, Tabary M,
Rayzan E and Rezaei N: Lymphoma in the setting of autoimmune
diseases: A review of association and mechanisms. Crit Rev Oncol
Hematol. 150(102945)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Stern M, Buser AS, Lohri A, Tichelli A and
Nissen-Druey C: Autoimmunity and malignancy in hematology-more than
an association. Crit Rev Oncol Hematol. 63:100–110. 2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ehrenfeld M, Abu-Shakra M, Buskila D and
Shoenfeld Y: The dual association between lymphoma and
autoimmunity. Blood Cells Mol Dis. 27:750–756. 2001.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Váróczy L, Gergely L, Zeher M, Szegedi G
and Illés A: Malignant lymphoma-associated autoimmune diseases-a
descriptive epidemiological study. Rheumatol Int. 22:233–237.
2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Smedby KE, Hjalgrim H, Askling J, Chang
ET, Gregersen H, Porwit-MacDonald A, Sundström C, Akerman M, Melbye
M, Glimelius B and Adami HO: Autoimmune and chronic inflammatory
disorders and risk of non-Hodgkin lymphoma by subtype. J Natl
Cancer Inst. 98:51–60. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mariette X: Lymphomas in patients with
Sjögren's syndrome: Review of the literature and physiopathologic
hypothesis. Leuk Lymphoma. 33:93–99. 1999.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cellier C, Delabesse E, Helmer C, Patey N,
Matuchansky C, Jabri B, Macintyre E, Cerf-Bensussan N and Brousse
N: Refractory sprue, coeliac disease, and enteropathy-associated
T-cell lymphoma. French coeliac disease study group. Lancet.
356:203–208. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kaul A, Gordon C, Crow MK, Touma Z,
Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G and Hughes G:
Systemic lupus erythematosus. Nat Rev Dis Primers.
2(16039)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bernatsky S, Ramsey-Goldman R, Rajan R,
Boivin JF, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S,
Ginzler E, et al: Non-Hodgkin's lymphoma in systemic lupus
erythematosus. Ann Rheum Dis. 64:1507–1509. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Azrielant S, Tiosano S, Watad A, Mahroum
N, Whitby A, Comaneshter D, Cohen AD and Amital H: Correlation
between systemic lupus erythematosus and malignancies: A
cross-sectional population-based study. Immunol Res. 65:464–469.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pettersson T, Pukkala E, Teppo L and
Friman C: Increased risk of cancer in patients with systemic lupus
erythematosus. Ann Rheum Dis. 51:437–439. 1992.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cibere J, Sibley J and Haga M: Systemic
lupus erythematosus and the risk of malignancy. Lupus. 10:394–400.
2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sweeney DM, Manzi S, Janosky J, Selvaggi
KJ, Ferri W, Medsger TA Jr and Ramsey-Goldman R: Risk of malignancy
in women with systemic lupus erythematosus. J Rheumatol.
22:1478–1482. 1995.PubMed/NCBI
|
|
16
|
Abu-Shakra M, Gladman DD and Urowitz MB:
Malignancy in systemic lupus erythematosus. Arthritis Rheum.
39:1050–1054. 1996.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mellemkler L, Andersen V, Linet MS,
Gridley G, Hoover R and Olsen JH: Non-Hodgkin's lymphoma and other
cancers among a cohort of patients with systemic lupus
erythematosus. Arthritis Rheum. 40:761–768. 1997.PubMed/NCBI View Article : Google Scholar
|
|
18
|
King JK and Costenbader KH:
Characteristics of patients with systemic lupus erythematosus (SLE)
and non-Hodgkin's lymphoma (NHL). Clin Rheumato. 26:1491–1494.
2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cush JJ: Rheumatoid arthritis: Early
diagnosis and treatment. Med Clin North Am. 105:355–365.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gridley G, McLaughlin JK, Ekbom A,
Klareskog L, Adami HO, Hacker DG, Hoover R and Fraumeni JF Jr:
Incidence of cancer among patients with rheumatoid arthritis. J
Natl Cancer Inst. 85:307–311. 1993.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Isomäki HA, Hakulinen T and Joutsenlahti
U: Excess risk of lymphomas, leukemia and myeloma in patients with
rheumatoid arthritis. J Chron Dis. 31:691–696. 1978.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mellemkjaer L, Linet MS, Gridley G, Frisch
M, Møller H and Olsen JH: Rheumatoid arthritis and cancer. Eur J
Cancer. 32A:1753–1757. 1996.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kauppi M, Pukkala E and Isomäki H:
Elevated incidence of hematologic malignancies in patients with
Sjögren's syndrome compared with patients with rheumatoid arthritis
(Finland). Cancer Causes Control. 8:201–204. 1997.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Prior P: Cancer and rheumatoid arthritis:
epidemiologic considerations. Am J Med. 78:15–21. 1985.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hakulinen T, Isomaki H and Knekt P:
Rheumatoid arthritis and cancer studies based on linking nationwide
registries in Finland. Am J Med. 78:29–32. 1985.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Silman AJ, Petrie J, Hazleman B and Evans
SJ: Lymphoproliferative cancer and other malignancy in patients
with rheumatoid arthritis treated with azathioprine: A 20 year
follow up study. Ann Rheum Dis. 47:988–992. 1988.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mariette X, Cazals-Hatem D, Warszawki J,
Liote F, Balandraud N and Sibilia J: Investigators of the Club
Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis
patients treated with methotrexate: A 3-year prospective study in
France. Blood. 99:3909–3915. 2002.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kinlen LJ: Incidence of cancer in
rheumatoid arthritis and other disorders after immunosuppressive
treatment. Am J Med. 78:44–49. 1985.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Thorne I and Sutcliffe N: Sjögren's
syndrome. Br J Hosp Med (Lond). 78:438–442. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shiboski CH, Shiboski SC, Seror R,
Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H,
Vitali C, Bowman SJ, et al: 2016 American college of
rheumatology/European league against rheumatism classification
criteria for primary Sjögren's syndrome: A consensus and
data-driven methodology involving three international patient
cohorts. Arthritis Rheumatol. 69:35–45. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sebastian A, Szachowicz A and Wiland P:
Classification criteria for secondary Sjögren's syndrome. Current
state of knowledge. Reumatologia. 57:277–280. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kassan SS, Thomas TL, Moutsopoulos HM,
Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL and Chused TM:
Increased risk of lymphoma in sicca syndrome. Ann Intern Med.
89:888–892. 1978.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Váróczy L, Páyer E, Kádár Z, Gergely L,
Miltényi Z, Magyari F, Szodoray P and Illés A: Malignant lymphomas
and autoimmunity-a single center experience from Hungary. Clin
Rheumatol. 31:219–224. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zintzaras E, Voulgarelis M and
Moutsopoulos H: The risk of lymphoma development in autoimmune
diseases: A meta-analysis. Arch Intern Med. 165:2337–2344.
2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Pertovaara M, Pukkala E, Laippala P,
Miettinen A and Pasternack A: A longitudinal cohort study of
Finnish patients with primary Sjögren's syndrome: Clinical,
immunological, and epidemiological aspects. Ann Rheum Dis.
60:467–472. 2001.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Bernatsky S, Ramsey-Goldman R and Clarke
A: Malignancy and autoimmunity. Curr Opin Rheumatol. 18:129–134.
2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shaffer AL, Rosenwald A and Staudt LM:
Lymphoid malignancies: The dark side of B-cell differentiation. Nat
Rev Immunol. 2:920–932. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
38
|
Ekström K, Hjalgrim H, Brandt L, Baecklund
E, Klareskog L, Ekbom A and Askling J: Risk of malignant lymphomas
in patients with rheumatoid arthritis and in their first-degree
relatives. Arthritis Rheum. 48:963–970. 2003.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Grulich AE, Vajdic CM and Cozen W: Altered
immunity as a risk factor for non-Hodgkin lymphoma. Cancer
Epidemiol Biomarkers Prev. 16:405–408. 2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Peng Z, Liang X, Lin X, Lin W, Lin Z and
Wei S: Exploration of the molecular mechanisms, shared gene
signatures, and MicroRNAs between systemic lupus erythematosus and
diffuse large B cell lymphoma by bioinformatics analysis. Lupus.
31:1317–1327. 2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Li H, Yu L, Zhang X, Shang J and Duan X:
Exploring the molecular mechanisms and shared gene signatures
between rheumatoid arthritis and diffuse large B cell lymphoma.
Front Immunol. 13(1036239)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Mackay LR and Rose NR: Autoimmunity and
lymphoma: Tribulations of B cells. Nature Immunol. 2:793–795.
2001.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wotherspoon AC, Doglioni C, Diss TC, Pan
L, Moschini A, de Boni M and Isaacson PG: Regression of primary
lowgrade B-cell gastric lymphoma of mucosa-associated lymphoid
tissue type after eradication of Helicobacter pylori. Lancet.
324:575–577. 1993.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Mariette X: Lymphomas complicating
Sjögren's syndrome and hepatitis C virus infection may share a
common pathogenesis: Chronic stimulation of rheumatoid factor B
cells. Ann Rheum Dis. 60:1007–1010. 2001.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Smedby KE, Baecklund E and Askling J:
Malignant lymphomas in autoimmunity and inflammation: A review of
risks, risk factors, and lymphoma characteristics. Cancer Epidemiol
Biomarkers Prev. 15:2069–2077. 2006.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Firestein GS: Evolving concepts of
rheumatoid arthritis. Nature. 423:356–361. 2003.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Bernatsky S, Clarke A and Ramsey-Goldman
R: Malignancy and systemic lupuserythematosus. Curr Rheumatol Rep.
4:351–358. 2002.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Yamamoto K: Pathogenesis of Sjogren's
syndrome. Autoimmun Rev. 2:13–18. 2003.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Baecklund E, Askling J, Rosenquist R,
Ekbom A and Klareskog L: Rheumatoid arthritis and malignant
lymphomas. Curr Opin Rheumatol. 16:254–261. 2004.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lenz G and Staudt LM: Aggressive
lymphomas. N Engl J Med. 362:1417–1429. 2010.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Jones SA and Jenkins BJ: Recent insights
into targeting the IL-6 cytokine family in inflammatory diseases
and cancer. Nat Rev Immunol. 18:773–789. 2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Qin B, Zhou Z, He J, Yan C and Ding S:
IL-6 inhibits starvation-induced autophagy via the STAT3/Bcl-2
signaling pathway. Sci Rep. 5(15701)2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Lan Q, Zheng T, Rothman N, Zhang Y, Wang
SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, et al:
Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to
non-Hodgkin lymphoma. Blood. 107:4101–4108. 2006.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cortes J and Kurzrock R: Interleukin-10 in
non-Hodgkin's lymphoma. Leuk Lymphoma. 26:251–259. 1997.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Khatri VP and Caligiuri MA: A review of
the association between interleukin-10 and human B-cell
malignancies. Cancer Immunol Immunother. 46:239–244.
1998.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Emilie D, Zou W, Fior R, Llorente L,
Durandy A, Crevon MC, Maillot MC, Durand-Gasselin I, Raphael M,
Peuchmaur M and Galamaud P: Production and roles of IL-6, IL-10,
and IL-13 in B-lymphocyte malignancies and in B-lymphocyte
hyperactivity of HIV infection and autoimmunity. Methods.
11:133–142. 1997.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Rothman N, Skibola CF, Wang SS, Morgan G,
Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, et
al: Genetic variation in TNF and IL10 and risk of non-Hodgkin
lymphoma: A report from the InterLymph consortium. Lancet Oncol.
7:27–38. 2006.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Szodoray P and Jonsson R: The BAFF/APRIL
system in systemic autoimmune diseases with a special emphasis on
Sjögren's syndrome. Scand J Immunol. 62:421–428. 2005.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Novak AJ, Grote DM, Stenson M, Ziesmer SC,
Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF,
et al: Expression of BLyS and its receptors in B-cell non-Hodgkin
lymphoma: Correlation with disease activity and patient outcome.
Blood. 104:2247–2253. 2004.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Baecklund E, Iliadou A, Askling J, Ekbom
A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N,
Sundström C and Klareskog L: Association of chronic inflammation,
not its treatment, with increased lymphoma risk in rheumatoid
arthritis. Arthritis Rheum. 54:692–701. 2006.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Bachman TR, Sawitzke AD, Perkins SL, Ward
JH and Cannon GW: Methotrexate-associated lymphoma in patients with
rheumatoid arthritis: Report of two cases. Arthritis Rheum.
39:325–329. 1996.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Baltus JA, Boersma JW, Hartman AP and
Vandenbroucke JP: The occurrence of malignancies in patients with
rheumatoid arthritis treated with cyclophosphamide: A controlled
retrospective follow-up. Ann Rheum Dis. 42:368–373. 1983.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Symmons DP, Ahern M, Bacon PA, Hawkins CF,
Amlot PL, Jones EL, Prior P and Scott DL: Lymphoproliferative
malignancy in rheumatoid arthritis: A study of 20 cases. Ann Rheum
Dis. 43:132–135. 1984.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Ekström Smedby K, Vajdic CM, Falster M,
Engels EA, Martínez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori
Costantini A, Bracci PM, et al: Autoimmune disorders and risk of
non-Hodgkin lymphoma subtypes: A pooled analysis within the
InterLymph consortium. Blood. 111:4029–4038. 2008.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Bernatsky S, Ramsey-Goldman R, Joseph L,
Boivin JF, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Nived
O, Petri MA, et al: Lymphoma risk in systemic lupus: Effects of
disease activity versus treatment. Ann Rheum Dis. 73:138–142.
2014.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Wolfe F and Michaud K: Lymphoma in
rheumatoid arthritis: The effect of methotrexate and anti-tumor
necrosis factor therapy in 18,572 patients. Arthritis Rheum.
50:1740–1751. 2004.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Leombruno JP, Einarson TR and Keystone EC:
The safety of anti-tumour necrosis factor treatments in rheumatoid
arthritis: Meta and exposure-adjusted pooled analyses of serious
adverse events. Ann Rheum Dis. 68:1136–1145. 2009.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Askling J, Fored CM, Baecklund E, Brandt
L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek
P, et al: Haematopoietic malignancies in rheumatoid arthritis:
Lymphoma risk and characteristics after exposure to tumour necrosis
factor antagonists. Ann Rheum Dis. 64:1414–1420. 2005.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Wolfe F and Michaud K: The effect of
methotrexate and anti-tumor necrosis factor therapy on the risk of
lymphoma in rheumatoid arthritis in 19,562 patients during 89,710
person-years of observation. Arthritis Rheum. 56:1433–1439.
2007.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Royer B, Cazals-Hatem D, Sibilia J,
Agbalika F, Cayuela JM, Soussi T, Maloisel F, Clauvel JP, Brouet JC
and Mariette X: Lymphomas in patients with Sjogren's syndrome are
marginal zone B-cell neoplasms, arise in diverse extranodal and
nodal sites, and are not associated with viruses. Blood.
90:766–775. 1997.PubMed/NCBI
|
|
71
|
Ghesquières H, Berger F, Felman P,
Callet-Bauchu E, Bryon PA, Traverse-Glehen A, Thieblemont C,
Baseggio L, Michallet AS, Coiffier B and Salles G:
Clinicopathologic characteristics and outcome of diffuse large
B-cell lymphomas presenting with an associated low-grade component
at diagnosis. J Clin Oncol. 24:5234–5241. 2006.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Zucca E, Conconi A, Pedrinis E, Cortelazzo
S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M,
Devizzi L, et al: Nongastric marginal zone B-cell lymphoma of
mucosa-associated lymphoid tissue. Blood. 101:2489–2495.
2003.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Smedby KE, Askling J, Mariette X and
Baecklund E: Autoimmune and inflammatory disorders and risk of
malignant lymphomas-an update. J Intern Med. 264:514–527.
2008.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Cerchietti LC, Yang SN, Shaknovich R,
Hatzi K, Polo JM, Chadburn A, Dowdy SF and Melnick A: A
peptomimetic inhibitor of BCL6 with potent antilymphoma effects in
vitro and in vivo. Blood. 113:3397–3405. 2009.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Gopal AK, Kahl BS, de Vos S,
Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR,
Martin P, Viardot A, et al: PI3Kδ inhibition by idelalisib in
patients with relapsed indolent lymphoma. N Engl J Med.
370:1008–1018. 2014.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Nogai H, Dörken B and Lenz G: Pathogenesis
of non-Hodgkin's lymphoma. J Clin Oncol. 29:1803–1811.
2011.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Hiddemann W: Non-Hodgkin's
lymphomas-current status of therapy and future perspectives. Eur J
Cancer. 31A:2141–2145. 1995.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Nowakowski GS and Czuczman MS: ABC, GCB,
and double-hit diffuse large B-cell lymphoma: Does subtype make a
difference in therapy selection? Am Soc Clin Oncol Educ Book.
35:e449–e457. 2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Sehn LH, Donaldson J, Chhanabhai M,
Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli
JJ, Sutherland J, et al: Introduction of combined CHOP plus
rituximab therapy dramatically improved outcome of diffuse large
B-cell lymphoma in British Columbia. J Clin Oncol. 23:5027–5033.
2005.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Forstpointner R, Dreyling M, Repp R,
Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F,
Rohrberg R, et al: The addition of rituximab to a combination of
fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly
increases the response rate and prolongs survival as compared with
FCM alone in patients with relapsed and refractory follicular and
mantle cell lymphomas: Results of a prospective randomized study of
the German low-grade lymphoma study group. Blood. 104:3064–3071.
2004.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Marcus R, Imrie K, Belch A, Cunningham D,
Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo
J, et al: CVP chemotherapy plus rituximab compared with CVP as
first-line treatment for advanced follicular lymphoma. Blood.
105:1417–1423. 2005.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Coiffier B, Lepage E, Briere J, Herbrecht
R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G,
Gaulard P, et al: CHOP chemotherapy plus rituximab compared with
CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med. 346:235–242. 2002.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Wilson WH, Gerecitano JF, Goy A, de Vos S,
Kenkre VP, Barr PM, Blum KA, Shustov AR, Advani RH, Lih J, et al:
The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib
(PCI-32765), has preferential activity in the ABC subtype of
relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL):
Interim results of a multicenter, open-label, phase 2 study. Blood.
120(686)2012.
|
|
84
|
Friedberg JW, Sharman J, Sweetenham J,
Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S,
Sinha R, Leonard JP, et al: Inhibition of Syk with fostamatinib
disodium has significant clinical activity in non-Hodgkin lymphoma
and chronic lymphocytic leukemia. Blood. 115:2578–2585.
2010.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Valla K, Flowers CR and Koff JL: Targeting
the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin
Investig Drugs. 27:513–522. 2018.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Aw A and Brown JR: Current status of
Bruton's tyrosine kinase inhibitor development and use in B-cell
malignancies. Drugs Aging. 34:509–527. 2017.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Smith SM, van Besien K, Karrison T, Dancey
J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, et
al: Temsirolimus has activity in non-mantle cell non-Hodgkin's
lymphoma subtypes: The University of Chicago phase II consortium. J
Clin Oncol. 28:4740–4746. 2010.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Pourdehnad M, Truitt ML, Siddiqi IN,
Ducker GS, Shokat KM and Ruggero D: Myc and mTOR converge on a
common node in protein synthesis control that confers synthetic
lethality in Myc-driven cancers. Proc Natl Acad Sci USA.
110:11988–11993. 2013.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Smolewski P and Rydygier D: Efficacy and
safety of idelalisib for the treatment of indolent B-cell
malignancies. Expert Opin Pharmacother. 21:1915–1926.
2020.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Souers AJ, Leverson JD, Boghaert ER,
Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH,
Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2
inhibitor, achieves antitumor activity while sparing platelets. Nat
Med. 19:202–208. 2013.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Vandenberg CJ and Cory S: ABT-199, a new
Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive
Myc-driven mouse lymphomas without provoking thrombocytopenia.
Blood. 121:2285–2288. 2013.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Lin VS, Xu ZF, Huang DCS and Thijssen R:
BH3 mimetics for the treatment of B-cell malignancies-insights and
lessons from the clinic. Cancers (Basel). 12(3353)2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Davids MS, Roberts AW, Seymour JF, Pagel
JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH,
et al: Phase I first-in-human study of venetoclax in patients with
relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol.
35:826–833. 2017.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Klanova M and Klener P: BCL-2 proteins in
pathogenesis and therapy of B-cell non-Hodgkin lymphomas. Cancers
(Basel). 12(938)2020.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Nademanee A: Transplantation for
non-Hodgkin lymphoma. Expert Rev Hematol. 2:425–442.
2009.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Bhatt VR and Vose JM: Hematopoietic stem
cell transplantation for non-Hodgkin lymphoma. Hematol Oncol Clin
North Am. 28:1073–1095. 2014.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Turunen A, Valtola J, Partanen A, Ropponen
A, Kuittinen O, Kuitunen H, Vasala K, Ågren L, Penttilä K, Keskinen
L, et al: Autograft cellular composition and outcome in NHL
patients: Results of the prospective multicenter GOA study. Leuk
Lymphoma. 61:2082–2092. 2020.PubMed/NCBI View Article : Google Scholar
|
